Participant‐reported pain relief of 30% or greater · adults with fibromyalgia
Mirtazapine may leads to higher participant‐reported pain relief of 30% or greater (moderate… compared with placebo (low certainty).
1 finding from 1 review
Oral mucositis (moderate to severe) · Adults receiving chemotherapy alone for colorectal cancer
Intestinal trefoil factor (ITF), oral spray led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Adults with cancer receiving treatment
Epidermal growth factor (EGF), oral spray showed no clear difference in oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
2 findings from 1 review
Oral mucositis (moderate to severe) · Adults receiving bone marrow/stem cell transplantation after conditioning therapy for haematological cancers
Erythropoietin mouthwash led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… may leads to lower oral mucositis (moderate to severe) compared with placebo (low certainty).
3 findings from 1 review
RR 0.89 [0.80, 0.99]
6 studies · 852 participants
Low
RR 0.91 [0.83, 1.00]
3 studies · 471 participants
Moderate
RR 0.56 [0.45, 0.70]
4 studies · 344 participants
Moderate
Patient response: moderate or severe pain at 1 day postoperative · People with maxillary palatally displaced (impacted) canines, unilateral or bilateral (children/adolescents; mean ages 14.2 to 17.5 years)
Open surgical exposure showed no clear difference in patient response: moderate or severe pain at 1 day postoperative compared with closed surgical exposure; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Adults with cancer receiving treatment
It is very uncertain whether granulocyte-macrophage colony-stimulating factor (GM-CSF) changes oral mucositis (moderate to severe) compared with placebo or no treatment (very low certainty).
2 findings from 1 review
Oral mucositis (moderate to severe) · Adults receiving radiotherapy to the head and neck
Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in oral mucositis (moderate to severe) compared with sucralfate mouthwash; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone
Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (moderate to severe) compared with chlorhexidine mouthwash; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Children receiving bone marrow/stem cell transplantation after conditioning therapy for mixed cancers
Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single… showed no clear difference in oral mucositis (moderate to severe) compared with granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple…; GRADE not reported.
1 finding from 1 review
Women with moderate or severe pain (measured by visual analogue scale) · Women in labour where operative delivery was not anticipated. (Women were above 16 years old and between 28 gestational weeks and full…
It is very uncertain whether selective changes women with moderate or severe pain (measured by visual analogue scale) compared with routine episiotomy: all vaginal births where operative vaginal… (very low certainty).
1 finding from 1 review
Moderate/severe disability at 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in moderate/severe disability at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Death or moderate/severe disability at 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in death or moderate/severe disability at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Venous thrombo‐embolism (DVT or PE): CEE 0.625 mg (moderate dose) · relatively healthy postmenopausal women
Oestrogen‐only hormone therapy (HT) showed no clear difference in venous thromboembolism (DVT or PE): CEE 0.625 mg (moderate dose) compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
⊕⊕⊕⊝moderate (1 study) · Healthcare workers
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Complication: renal complications (moderate or severe) (30‐day) · people diagnosed with RAAA
Emergency endovascular aneurysm repair showed no clear difference in complication: renal complications (moderate or severe) (30‐day) compared with conventional open repair (low certainty).
1 finding from 1 review
Moderate benefit · adults with postherpetic neuralgia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
IMMPACT definition ‐ any at least moderate pain benefit · adults with postherpetic neuralgia
1 finding from 1 review
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · people with diabetic peripheral neuropathy
1 finding from 1 review
Neurological function at hospital discharge, measured by cerebral performance category (CPC) · Patients with non‐trauma related out‐of‐hospital cardiac arrest
Continuous chest compression alone showed no clear difference in neurological outcomes at hospital discharge Measured as 'good' or… compared with interrupted chest compression plus artificial ventilation (moderate certainty).
1 finding from 1 review